BioTuesdays
MiMedx Group

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

Acutes-Medical-Logo

WB cuts Acutus Medical to market perform

William Blair downgraded Acutus Medical (NASDAQ:AFIB) to “market perform,” saying “early-stage growing pains lead to lower than expected guidance.” The stock closed at $16.83, down $2.23, on March 18. Analyst Margaret...

Merus Logo

SVB Leerink starts Merus at OP; PT $33

SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...

Oncorus-Logo

Maxim starts Oncorus at buy; PT $35

Maxim Group initiated coverage of Oncorus (NASDAQ:ONCR) with a “buy” rating and price target of $35. The stock closed at $16.39 on March 15. Oncorus is developing oncolytic viral (OV) immunotherapies for solid tumors...

TransMedics logo

Canaccord ups TransMedics PT to $79 from $46

Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...

Seelos Therapeutics Logo

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

Selecta Biosciences

WB ups Selecta Biosciences to outperform

William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...

Medicinova inc logo

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

Maxim starts Panbela Therapeutics at buy; PT $8

Maxim Group launched coverage of Panbela Therapeutics (NASDAQ:PBLA) with a “buy” rating and $8 price target. The stock closed at $4.17 on March 9. The company’s polyamine metabolic inhibitor drug candidate, SBP...

NexImmune-Logo

Cantor starts NexImmune at OW, PT $35

Cantor Fitzgerald launched coverage of NexImmune (NASDAQ:NEXI) with an “overweight” rating and price target of $35. The stock closed at $20.63 on March 8. NexImmune is developing a novel approach in cancer immunotherapy...

Talis-Logo

BTIG starts Talis Biomedical at buy; PT $18

BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...

Akebia-Logo

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

oncosec

BTIG starts OncoSec Medical at buy; PT $10

BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...

TransMedics logo

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

NLS-Pharmaceutics-Logo

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

Heat Biologics

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.